Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–215 of 215 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Valproic Acid (VPA) Clear all

Conditions: Shock,Hemorrhagic
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium (Depakote ER); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 18
States / cities: Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 15 more

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism
Interventions: divalproex sodium, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 4 Years to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Louisville, Kentucky • Boston, Massachusetts

Conditions: Mixed Mania Bipolar Disorder
Interventions: Lamotrigine, Sodium Valproate; Drug
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy, Mental Retardation, Developmental Disabilities
Interventions: Swallow instruction; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 4 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions: Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid; Biological · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Optimized Treatment (OPT); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Bipolar Depression
Interventions: Lurasidone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Costa Mesa, California • Riverside, California • San Diego, California + 16 more

Conditions: ALPS, Hypersplenism, Lymphadenopathy
Interventions: Valproic Acid, CT Scan, Blood Sample; Drug · Procedure
Lead sponsor: Koneti Rao; NIH
Eligibility: 2 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Shock,Hemorrhagic, Trauma
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Alcoholism, Bipolar Disorder
Interventions: sodium valproate; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy, Obesity, Pharmacokinetics
Interventions: Valproic acid; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 21 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania
Interventions: Divalproex, Placebo; Drug · Other
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mood Disorders
Interventions: Divalproex Sodium (Depakote); Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 7 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer Disease
Interventions: Valproate, Placebo; Drug
Lead sponsor: Alzheimer's Disease Cooperative Study (ADCS); Other
Eligibility: 55 Years to 90 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 46
States / cities: Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more

Conditions: Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions: Valproic Acid (VPA), Standard of care treatment + normal saline; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 6 more

Conditions: Bipolar Disorder
Interventions: Family-Focused Treatment Plus Pharmacotherapy, Enhanced Care Plus Pharmacotherapy; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 17 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Boulder, Colorado • Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Epilepsy
Interventions: Divalproex; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer Disease
Interventions: Divalproex, Lithium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar Disorder, Metabolic Syndrome
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bipolar Disorder
Interventions: divalproex or olanzapine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium

Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania

Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

Drug Treatment for Alcoholics With Bipolar Disorder

A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights

Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Valproate in Dementia (VALID)

Valproic AcId for Traumatic BRAin INjury Trial

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

Effect of Lithium and Divalproex in Alzheimer's Disease

Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder